Foamix Pharmaceuticals

February 21, 2020

Upcoming events – Filgotinib's ulcerative colitis data and serlopitant takes on pruritus

Gilead and Galapagos's filgotinib might not be a match for Rinvoq in ulcerative colitis, while Menlo needs to prove serlopitant works after previous setbacks.

Foamix Pharmaceuticals

Upcoming events – Filgotinib's ulcerative colitis data and serlopitant takes on pruritus

US FDA approval tracker: October

Go or no go? Novartis eyes a big new growth driver

Perseverance pays off for Foamix

Dermira in a spot of bother after acne failure

Upcoming events – Another SGLT2 approval due and stem cell data for Mesoblast

Strong small cap performance drives second-quarter gains

Mid-cap biopharma stocks pick up in the first quarter

Interview – Foamix spots dermatology opportunity

Snippet roundup: Wins for AcelRx, Foamix and SGLT2 developers.

IPOs surge in Q3 as investor enthusiasm shows no sign of waning

Latest Reports

Biopharma Quarterly Round Up (Q3 2021)

Covid Round Up (2021)

Editor's Picks

The bubble bursts for biotech stocks

Ash 2021 preview – as competition grows Autolus monetises

Ash 2021 late-breakers enable neat comparisons

What Novartis could buy with its windfall

Fate buries bad data and moves on